Ligand id: 8257

Name: sifalimumab

Compound class Antibody
International Nonproprietary Names
INN number INN
9135 sifalimumab
MDX-1103 | MEDI-545 | MEDI545
Sifalimumab is a monoclonal antibody targeting interferon α1 (IFNA1), being developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Sequence BLAST using the heavy and light chain variable regions of sifalimumab provides 100% matches to sequences patented with application US7741449 [12]. The sequence matches identify sifalimumab as clone 13H5 in the patent.
Database Links
Specialist databases
IMGT/mAb-DB 322
Other databases
GtoPdb PubChem SID 249565937
Search PubMed clinical trials sifalimumab
Search PubMed titles sifalimumab
Search PubMed titles/abstracts sifalimumab
Wikipedia Sifalimumab